Evidence map›Paper›PMID 27489505›Full record

ReviewInternational journal of biological sciences2016

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Yi Li, Ji Wang, Xiaowei Ma, Li Tan, Yanli Yan, Chaofan Xue, Beina Hui, Rui Liu, Hailin Ma, Juan Ren

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 152 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04814784 unknown statusnot on this mapstarted 2021, after this paper: background citation

Retrospective Study Comparing Neoadjuvent Short Course of Radiotherapy to Conventional Chemoradiation in Cancer Rectum

TypeobservationalSponsorAmany sayed AbassRan2021 to 2022Enrolled48ConditionsRectal AdenocarcinomaArmsNeoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum
NCT06097416 phase3not yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a/b/c) Rectal Cancer

TypeinterventionalSponsorSt. James's Hospital, IrelandRan2024 to 2030Enrolled100ConditionsRectal CancerArmsNeoadjuvant Chemoradiotherapy, Total Neoadjuvant Therapy
3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Changes in fatigue in rectal cancer patients before and after therapy: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Predicting locally advanced rectal cancer response to neoadjuvant therapy withEuropean journal of nuclear medicine and molecular imaging · 2019
    Trial
  11. Trial
  12. Article
  13. BaselineAnnals of nuclear medicine · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi Li2. Department of Chemotherapy, Oncology Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Ji Wang3. Intensive Care Unit, China Mei Tan General Hospital, ChaoYang, Beijing 100028, P.R. China.
Xiaowei Ma4. Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Li Tan4. Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Yanli Yan4. Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Chaofan Xue4. Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Beina Hui1. Department of Radiotherapy, Oncology Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Rui Liu1. Department of Radiotherapy, Oncology Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Hailin Ma1. Department of Radiotherapy, Oncology Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Juan Ren1. Department of Radiotherapy, Oncology Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemradiotherapy than high rectal cancer. It needs to refine the selection of appropriate patients and irradiation modes for neoadjuvant chemoradiotherapy. Different therapeutic reactions to neoadjuvant chemoradiotherapy affect the type of surgical techniques, hence calling for the need of much attention. Furthermore, many problems such as accurate staging before surgery, selection of suitable neoadjuvant chemoradiotherapy method, and sensitivity prediction to preoperative radiotherapy need to be well settled.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyFemaleHumansMaleNeoadjuvant TherapyNeoplasm StagingRectal Neoplasmspreoperative concurrent chemoradiotherapyRectal cancer

Identifiers

PMID27489505
PMCPMC4971740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.